BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Leukemia AND MET, RCCP2, 4233, ENSG00000105976, P08581, HGFR, AUTS9 AND Treatment
571 results:

  • 1. Intracranial residual lesions following early intensification in a patient with T-cell acute lymphoblastic leukemia: a case report.
    Nagamatsu Y; Isoda T; Inaji M; Oyama J; Niizato D; Tomomasa D; Mitsuiki N; Yamashita M; Kamiya T; Imai K; Kanegane H; Morio T; Takagi M
    BMC Pediatr; 2024 May; 24(1):304. PubMed ID: 38704558
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer (TOPAZ-1): patient-reported outcomes from a randomised, double-blind, placebo-controlled, phase 3 trial.
    Burris HA; Okusaka T; Vogel A; Lee MA; Takahashi H; Breder V; Blanc JF; Li J; Bachini M; Żotkiewicz M; Abraham J; Patel N; Wang J; Ali M; Rokutanda N; Cohen G; Oh DY
    Lancet Oncol; 2024 May; 25(5):626-635. PubMed ID: 38697156
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. A systematic review of combined surgery and brachytherapy approaches for children and young people with relapsed and refractory rhabdomyosarcoma (Local-REFoRMS).
    Ballantyne E; Evans C; Shepherd L; Fulbright H; Wakeling S; Phillips B; Morgan JE
    Pediatr Blood Cancer; 2024 Jun; 71(6):e30952. PubMed ID: 38566349
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. First-in-human study of JNJ-67571244, a CD33 × CD3 bispecific antibody, in relapsed/refractory acute myeloid leukemia and myelodysplastic syndrome.
    Narayan R; Piérola AA; Donnellan WB; Yordi AM; Abdul-Hay M; Platzbecker U; Subklewe M; Kadia TM; Alonso-Domínguez JM; McCloskey J; Bradford K; Curtis M; Daskalakis N; Guttke C; Safer K; Hiebert B; Murphy J; Li X; Duchin K; Esteban D
    Clin Transl Sci; 2024 Mar; 17(3):e13742. PubMed ID: 38494922
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. PHA-665752's Antigrowth and Proapoptotic Effects on HSC-3 Human Oral Cancer Cells.
    Yadav AK; Wang S; Shin YM; Jang BC
    Int J Mol Sci; 2024 Mar; 25(5):. PubMed ID: 38474118
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. Anlotinib Inhibits Cisplatin Resistance in Non-Small-Cell Lung Cancer Cells by Inhibiting MCL-1 Expression via met/STAT3/Akt Pathway.
    Wang L; Xu L; Han S; Zhu X
    Can Respir J; 2024; 2024():2632014. PubMed ID: 38468814
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. [Venetoclax Combined with CACAG Regimen in the treatment of Patients with Refractory/Relapse Acute Myeloid leukemia: A Prospective Clinical Study].
    Gao WJ; Yang JJ; Li M; Wen YN; Jiao YF; LE N; Liu YC; Wang N; Huang S; Dou LP
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2024 Feb; 32(1):90-95. PubMed ID: 38387905
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. Glasdegib with intensive/nonintensive chemotherapy in Japanese patients with untreated acute myeloid leukemia or high-risk myelodysplastic syndromes.
    Izutsu K; Ubukawa K; Morishita T; Onishi Y; Ishizawa K; Fujii Y; Kimura N; Yokochi M; Naoe T
    Cancer Sci; 2024 Apr; 115(4):1250-1260. PubMed ID: 38327103
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. meta-analysis of decitabine pretreatment-based allogeneic hematopoietic stem cell transplantation affecting transplantation-related complications and prognosis in patients with malignant hematological disease.
    Li L; Zhao Z; Li X
    Cell Mol Biol (Noisy-le-grand); 2023 Dec; 69(14):69-75. PubMed ID: 38279480
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. Measuring neurobehavioral side effects of corticosteroids in pediatric acute lymphoblastic leukemia: A scoping review.
    Bhasin S; Brown J; Dorste A; Samsel C; Vrooman LM; Muriel AC
    Pediatr Blood Cancer; 2024 Apr; 71(4):e30881. PubMed ID: 38263506
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. Maintenance therapy for chronic lymphocytic leukaemia.
    Lee CH; Wu YY; Huang TC; Lin C; Zou YF; Cheng JC; Chen PH; Jhou HJ; Ho CL
    Cochrane Database Syst Rev; 2024 Jan; 1(1):CD013474. PubMed ID: 38174814
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. Resisting the Resistance: Navigating BTK Mutations in Chronic Lymphocytic leukemia (CLL).
    Chirino A; Montoya S; Safronenka A; Taylor J
    Genes (Basel); 2023 Dec; 14(12):. PubMed ID: 38137005
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. Sabatolimab plus hypomethylating agents in previously untreated patients with higher-risk myelodysplastic syndromes (STIMULUS-MDS1): a randomised, double-blind, placebo-controlled, phase 2 trial.
    Zeidan AM; Ando K; Rauzy O; Turgut M; Wang MC; Cairoli R; Hou HA; Kwong YL; Arnan M; Meers S; Pullarkat V; Santini V; Malek K; Kiertsman F; Niolat J; Ramos PM; Menssen HD; Fenaux P; Miyazaki Y; Platzbecker U
    Lancet Haematol; 2024 Jan; 11(1):e38-e50. PubMed ID: 38065203
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. Expression of genes potentially involved in loss of response in patients with chronic myeloid leukemia.
    Benegas P; Ziegler B; Dieminger V; Bengió R; Zapata P; Larripa I; Ferri C
    Gene; 2024 Feb; 896():148047. PubMed ID: 38042214
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. Liver failure after treatment with inotuzumab and polychemotherapy including PEG-asparaginase in a patient with relapsed Philadelphia chromosome-negative acute lymphoblastic leukemia.
    Fischer D; Toenges R; Kiil K; Michalik S; Thalhammer A; Bug G; Gökbuget N; Lang F
    Ann Hematol; 2024 Feb; 103(2):489-498. PubMed ID: 37999763
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. Paediatric cancer burden in Namibia: A 10-year retrospective, analytical cohort study of patients admitted at Windhoek Central Hospital.
    Kaholongo NO; Mashingaidze-Mano R
    PLoS One; 2023; 18(11):e0292794. PubMed ID: 37972109
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. A comprehensive comparison between TBI vs non-TBI-based conditioning regimen in pediatric patients with acute lymphoblastic leukemia: A systematic review and meta-analysis.
    Ansari F; Behfar M; Jafari L; Mohseni R; Naji P; Karamlou Y; Amirzade-Iranaq MH; Hamidieh AA
    Leuk Res; 2023 Dec; 135():107416. PubMed ID: 37918224
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. Ex vivo drug response profiling for response and outcome prediction in hematologic malignancies: the prospective non-interventional SMARTrial.
    Liebers N; Bruch PM; Terzer T; Hernandez-Hernandez M; Paramasivam N; Fitzgerald D; Altmann H; Roider T; Kolb C; Knoll M; Lenze A; Platzbecker U; Röllig C; Baldus C; Serve H; Bornhäuser M; Hübschmann D; Müller-Tidow C; Stölzel F; Huber W; Benner A; Zenz T; Lu J; Dietrich S
    Nat Cancer; 2023 Dec; 4(12):1648-1659. PubMed ID: 37783805
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. treatment outcomes of childhood PICALM::MLLT10 acute leukaemias.
    Mark C; Meshinchi S; Joyce B; Gibson B; Harrison C; Bergmann AK; Goemans BF; Pronk CJH; Lapillonne H; Leverger G; Antoniou E; Schneider M; Attarbaschi A; Dworzak M; Stary J; Tomizawa D; Ebert S; Lejman M; Kolb EA; Schmiegelow K; Hasle H; Abla O
    Br J Haematol; 2024 Feb; 204(2):576-584. PubMed ID: 37743097
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. Efficacy of gilteritinib in comparison with alectinib for the treatment of ALK-rearranged non-small cell lung cancer.
    Ando C; Ichihara E; Nishi T; Morita A; Hara N; Takada K; Nakasuka T; Watanabe H; Kano H; Nishii K; Makimoto G; Kondo T; Ninomiya K; Fujii M; Kubo T; Ohashi K; Matsuoka KI; Hotta K; Tabata M; Maeda Y; Kiura K
    Cancer Sci; 2023 Nov; 114(11):4343-4354. PubMed ID: 37715310
    [TBL] [Abstract] [Full Text] [Related]  


    [Next]

    of 29.